BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS




 Key Statistics


Email:
Ownership:

Web Site: Bristol-Myers Squibb Company
Employees:
Symbol: BMY
 





Collaborations

Gilead Sciences, Inc. 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys, Inc.  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead Sciences, Inc. (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead Sciences, Inc. (Seattle, WA) 





 Company News
Bristol-Myers Squibb Company (BMY) Release: Secondary Analysis Of AMPLIFY-EXT Examining Predictors Of Hospitalization Presented At ESC Congress: Eliquis (Apixaban) Significantly Reduced The Risk Of All-Cause Hospitalization Versus Placebo In Patients With Venous Thromboembolism (VTE) 9/2/2014 1:24:03 PM
Bristol-Myers Squibb Company (BMY) To Take Part In Morgan Stanley (MST) Global Health Care Conference 9/2/2014 10:56:14 AM
Bristol-Myers Squibb Company (BMY) Gives Back Rights To Alder Biopharmaceuticals Inc.'s Promising Arthritis Drug Clazakizumab 9/2/2014 8:12:26 AM
Bristol-Myers Squibb Company (BMY) And Pfizer Inc. (PFE) To Present New Data On Eliquis® (Apixaban) At The European Society of Cardiology Congress 2014 8/20/2014 8:41:27 AM
Bristol-Myers Squibb Company (BMY) And Celgene (CELG) Enter Clinical Collaboration Agreement To Evaluate Immunotherapy And Chemotherapy Combination Regimen 8/20/2014 8:25:44 AM
Bristol-Myers Squibb Company (BMY) Release: European Commission Approves Eliquis (Apixaban) For The Treatment Of Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE), And Prevention Of Recurrent DVT And PE 7/29/2014 9:38:32 AM
Bristol-Myers Squibb Company (BMY) And Ono Pharmaceutical Company, Ltd. Announce Strategic Immuno-Oncology Collaboration In Japan, South Korea And Taiwan 7/24/2014 11:34:28 AM
Bristol-Myers Squibb Company (BMY) And Pfizer Inc. (PFE) Announce Enrollment Of First Patient In Phase IV EMANATE Trial To Assess Effectiveness And Safety Of Eliquis® (Apixaban) In Patients With NVAF Undergoing Cardioversion 7/17/2014 9:42:56 AM
Bristol-Myers Squibb Company (BMY) Announces Plans For Third Quarter Submission Of A Biologics License Application For Opdivo® (Nivolumab), An Investigational PD-1 Immune Checkpoint Inhibitor, For Previously Treated Advanced Melanoma 7/10/2014 10:03:51 AM
Bristol-Myers Squibb Company (BMY) Release: Japan Approves First All-Oral, Interferon- And Ribavirin-Free Hepatitis C Treatment, Daklinza® (Daclatasvir) And Sunvepra®(Asunaprevir) Dual Regimen 7/7/2014 11:27:00 AM
12345678910...